Noch Fragen? 0800 / 33 82 637

Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

Produktform: E-Buch Text Elektronisches Buch in proprietärem

Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.  To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1.  While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.  weiterlesen

Elektronisches Format: PDF

Sprache(n): Englisch

ISBN: 978-3-030-16550-5 / 978-3030165505 / 9783030165505

Verlag: Springer International Publishing

Erscheinungsdatum: 16.07.2019

Seiten: 120

Herausgegeben von Marianne Davies, Beth Eaby-Sandy

53,49 € inkl. MwSt.
Recommended Retail Price
kostenloser Versand

lieferbar - Lieferzeit 10-15 Werktage

zurück